Novartis

News

Jimenez to step down as Novartis chief, Narasimhan takes ove...

Joe Jimenez is to step down after eight years as Novartis chief executive, and will be leaving on a high after last week’s first-in-class CAR-T approval.

News

Oxford BioMedica could get $100m following CAR-T approval

UK biotech will supply key component of Novartis' newly approved cancer cell therapy

News

Novartis and FDA hail 'historic' Kymriah, first ever approve...

In the end, the FDA took little more than six weeks to give final approval to Kymriah, the first ever CAR-T treatment.

Events

Partner Content

Tumour Models London 2017

Enhance Translational Decision Making

Events

Partner Content

CRISPR & Precision Gene Editing Congress - Berlin 2017

CRISPR & Precision Gene Editing Congress Berlin 2017

News

Show ambition with UK life sciences plan, Novartis tells gov...

Drugmaker concerned over access to new drugs

Jimenez to step down as Novartis chief, Narasimhan takes ove...

Oxford BioMedica could get $100m following CAR-T approval

Novartis and FDA hail 'historic' Kymriah, first ever approve...

Tumour Models London 2017

CRISPR & Precision Gene Editing Congress - Berlin 2017

Show ambition with UK life sciences plan, Novartis tells gov...

Australia starts probe into AI infiltration of Medicare

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks